A Year of Progress, A Future of Hope
Advancing Oncology: Reflections on a year of progress and purpose
As the year draws to a close, oncology research stands out for its remarkable advances—three milestones that represent renewed hope, greater precision, and a vision for the future of cancer care. Each breakthrough reflect the innovation and dedication that have defined this year in oncology. Here, we highlight three standout achievements that have shaped the landscape:
1. The Menin Breakthrough
Revumenib (Revuforj®), a first-in-class menin inhibitor, received FDA approval in October 2025 for relapsed/refractory acute myeloid leukaemia (AML) with an NPM1 mutation. Because menin plays a central role in certain leukaemias, this targeted therapy marks a significant shift: a molecularly precise treatment for a subset of AML patients who previously had very limited options.
2. A New Standard for Breast Cancer
Datopotamab deruxtecan (Datroway®), an antibody-drug conjugate (ADC), was approved for HR-positive, HER2-negative metastatic breast cancer after prior endocrine therapy and chemotherapy. By targeting TROP-2, this therapy delivers potent cytotoxic activity more precisely to cancer cells, poised to become poised to become a new standard of care for a challenging breast cancer subtype.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast
3. First-in-Human: First-in-Hope
At ASCO 2025, researchers introduced MDX2001, a tetraspecific T-cell engager-expander, in a phase 1/2a first-in-human trial for advanced solid tumours. This innovative “multi-armed” engager simultaneously draws in T cells, expands them, and guides them to tumours. It Represents an emerging next-generation immunotherapy that could lay the groundwork for entirely new treatment paradigms.
https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS2670
While these achievements reflect the broader industry progress in oncology, Fortrea’s role is to support innovators in shaping the future. Explore how Fortrea helps advance oncology development through tailored solutions for every stage of the clinical journey, from early-phase planning to post-approval support